Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer

Journal of Nuclear Medicine

Volumn 37, Issue 11, 1996, Pages 1853-1859

  Bardiès, Manuel ^b   Bardet, Stephane ^b   Faivre Chauvet, Alain ^b   Peltier, Patrick ^b   Douillard, Jean Yves ^b   Mahé, Marc ^b   Fiche, Maryse ^b   Lisbona, Albert ^b   Giacalone, Françoise ^b   Meyer, Pascal ^b   Gautherot, Emmanuel ^b   Rouvier, Eric ^b   Barbet, Jacques ^b   Chatal, Jean François ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b NONE

Author keywords

bispecific antibody; medullary thyroid cancer; small cell lung cancer; two step targeting

Indexed keywords

BISPECIFIC ANTIBODY; CALCITONIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; HAPTEN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F6 734; NEURON SPECIFIC ENOLASE; PENTETATE INDIUM; PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARTMENT MODEL; CONTROLLED STUDY; DOSIMETRY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME;

ANTIBODIES, BISPECIFIC; CARCINOMA, MEDULLARY; CARCINOMA, SMALL CELL; HAPTENS; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS;

EID: 10344241996     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 131I]-anti-B1 (anti-CD 20) antibody. N Engl J Med 1993;329:459-465.
2. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
3. Le Doussal JM, Gruaz-Guyon A, Martin M, et al. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990;50:3445-3452.
4. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al. Bispecific monoclonal antibody mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 1993;10:1662-1671.
5. Peltier P, Curtet C, Chatal JF, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-Indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993;34:1267-1273.
6. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bispecific and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-3130.
7. Baxter LT, Yuan F, Jain RK. Pharmacokinetic analysis of the perivascular distribution of bispecific antibodies and haptens: comparison with experimental data. Cancer Res 1992;52:5838-5844.
8. DeNardo GL, DeNardo SJ, Macey DJ, et al. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Srivastava SC, ed. Radiolabeled monoclonal antibodies for imaging and therapy. New York: Plenum; 1988:293-309.
9. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, 1988.
10. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Com 1993;14:587-595.
11. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50:1039s-1042s.
12. 111In-labeled monoclonal anti-CEA antibody fragment. J Nucl Med 1986;25:227-231.
13. Edington HD, Watson CG, Levine G, et al. Radioimmunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium-111-labeled monoclonal antibody to CEA. Surgery 1988;104:1004-1010.
14. 111In-labeled OC-125 antibody in cancer patients compared with the 19-9 antibody. Cancer Res 1987;47:6111-6117.
15. Kinuya S, Jeong JM, Garraestani K, et al. Effect of metabolism on retention of Indium-111-labeled monoclonal antibody in liver and blood. J Nucl Med 1994;35: 1851-1857.
16. Vaupel P. Oxygen supply to malignant tumors. In: Petersen HI, ed. Tumor blood circulation: angiogenesis, vascular morphology and blood flow of experimental and human tumors. Boca Raton: CRC Press; 1979:143.
17. Zanzonico P. Radioimmunotherapy of micrometastases: a continuing evolution. J Nucl Med 1992;33:2180-2183.
18. Thomas SR, Maxon HR, Kereiakes JG, et al. Quantitative external counting techniques enabling improved diagnostic and therapy decisions in patients with well-differentiated thyroid cancer. Radiology 1977;122:731-737.
19. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma J Nucl Med 1990;31:1257-1268.
20. Goldenberg DM, Horowitz JO, Sharkey RM, et al. Targeting, dosimetry and radioimmunotherapy of B-cell lymphoma with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548-564.
21. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry and radioimmunotherapy with iodine-131-labeled anti-CD 37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696-1711.